According to GlobalData, LUMIPULSE is one of 14 product lines sold in the US procalcitonin tests market; these product lines are sold by 13 different manufacturers. The price of the LUMIPULSE device can be viewed in GlobalData’s micro pricing report and can be retrieved according to purchase date, facility type, bed size, and geographical region. Buy the report here.
Smarter leaders trust GlobalData
The selling price or list price of a medical device is driven by numerous factors, such as therapy area and complexity of procedure, level of reimbursement, development costs, the number of competing manufacturers, product life cycle, and whether there have been any recent new technology or product launches.
In addition, the final selling pricing of medical devices is also impacted by the discounting policy of the manufacturer. Companies such as Fujirebio Diagnostics apply discounts for their devices based on their internal business strategy, inventory control, and monthly or quarterly sales targets. In addition, sale location can also affect the final selling price of a device, both in terms of geographical region and facility type. Prices for the same medical device often vary in hospitals and health systems versus outside of hospital facilities, for example if high volume healthcare institutions can negotiate discounts or rebates based on large purchase sizes.
Fujirebio Diagnostics overview
Fujirebio Diagnostics Inc (FDI), a subsidiary of Fujirebio Inc, is a healthcare diagnostic company that manufactures, markets and develops biomarker assays and in-vitro diagnostic products. The company’s products include OEM custom solutions, manual kits, serum products, multi-constituent controls, EIA kits, and other test kits, among others. Its serum products comprise enzyme conjugate stabilizer, glycated human hemoglobin animal serums, and nonglycated human haemoglobin, among others. FDI also provides reagents and controls, and manual assay products, among others. The company offers elisa antibody and antigen kits. It has its operations through its offices located in the US, Italy and Russia. FDI is headquartered in Malvern, Pennsylvania, the US.
For a complete picture of LUMIPULSE, Procalcitonin Tests pricing in the US, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Medical Intelligence Center Market Models are the gold standard of medical device market valuation, company share estimation and market trend forecasting. GlobalData uses a patient-based forecast model or installed base methodology to determine the market size for therapeutic indications and capital equipment expenditures. Estimates are based on a number of sources, including primary research—KOL and industry contact interviews—and secondary research, such as company reports, press releases, published articles, proprietary databases, and general news media.
